Literature DB >> 7512681

Diagnosis of growth-hormone deficiency in adults.

D M Hoffman1, A J O'Sullivan, R C Baxter, K K Ho.   

Abstract

There is no consensus as to the most appropriate method of diagnosing growth-hormone (GH) deficiency in adults. We have evaluated the relative diagnostic merits of measuring peak GH response to insulin-induced hypoglycaemia (insulin tolerance test), mean 24 h GH concentration derived from 20 min sampling, serum insulin-like growth factor I (IGF-I) concentrations, and serum IGF binding protein 3 (IGFBP-3) concentrations. These tests were undertaken in 23 patients considered GH deficient from extensive organic pituitary disease, and in 35 sex-matched normal subjects of similar age and body-mass index. Hypopituitary subjects had significantly lower stimulated peak GH, mean 24 h GH, IGF-I, and IGFBP-3 concentrations than normal subjects. The ranges of stimulated peak GH responses were clearly separated between the hypopituitary (< 0.2-3.1 ng/mL) and normal (5.3-42.5 ng/mL) groups, but mean 24 h GH, IGF-I, and IGFBP-3 concentrations overlapped. Mean 24 h GH concentrations were below assay sensitivity in 80% of hypopituitary subjects and 16% of normal subjects. 70% and 72%, respectively, of the IGF-I and IGFBP-3 values in hypopituitary subjects were within the range for normal subjects. We conclude that GH deficiency in adults is most reliably identified by stimulatory testing, and that IGF-I and IGFBP-3 are poor diagnostic tests of adult GH deficiency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512681     DOI: 10.1016/s0140-6736(94)90181-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  55 in total

1.  Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors.

Authors:  A Colao; G Cerbone; R Pivonello; M Klain; G Aimaretti; A Faggiano; C Di Somma; M Salvatore; G Lombardi
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 2.  Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management.

Authors:  A A Brandes; L M Pasetto; F Lumachi; S Monfardini
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

Review 3.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

4.  Diagnosis: a reappraisal of the diagnosis of growth hormone deficiency.

Authors:  Gudmundur Johannsson
Journal:  Nat Rev Endocrinol       Date:  2010-04       Impact factor: 43.330

Review 5.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

6.  Safety of the insulin tolerance test.

Authors:  P J Galloway; E McNeill; W F Paterson; M D C Donaldson
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

Review 7.  Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: the impact on bone mass.

Authors:  G Saggese; G I Baroncelli; T Vanacore; L Fiore; S Ruggieri; G Federico
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 8.  Making sense of gut feelings in the traumatic brain injury pathogenesis.

Authors:  Luiz Fernando Freire Royes; Fernando Gomez-Pinilla
Journal:  Neurosci Biobehav Rev       Date:  2019-05-16       Impact factor: 8.989

9.  Pituitary testing: a reappraisal.

Authors:  Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 10.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.